Officials with Adapt Pharma announced the FDA approval of Narcan (naloxone HCI) Nasal Spray additional dosing. The naloxone nasal spray will be available as a 2-mg formulation indicated for the emergency treatment of opioid overdose, as manifested by respiratory and/or central nervous system depression.

The FDA’s approval comes just 1 year after the 4-mg Narcan Nasal Spray was approved as the first of its kind, needle-free version of naloxone. Both formulations are ready-to-use concentrated naloxone nasal sprays intended for immediate administration as emergency treatment of opioid overdose.

The 2-mg formulation is approved for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.